186 related articles for article (PubMed ID: 37164838)
21. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1.
Landmesser U; Haghikia A; Leiter LA; Wright RS; Kallend D; Wijngaard P; Stoekenbroek R; Kastelein JJ; Ray KK
Cardiovasc Res; 2021 Jan; 117(1):284-291. PubMed ID: 32243492
[TBL] [Abstract][Full Text] [Related]
22. [Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].
Scheen AJ; Wallemacq C; Lancellotti P
Rev Med Liege; 2022 Dec; 77(12):745-751. PubMed ID: 36484754
[TBL] [Abstract][Full Text] [Related]
23. Inclisiran for the treatment of dyslipidemia.
Nishikido T; Ray KK
Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410
[TBL] [Abstract][Full Text] [Related]
24. Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein Reduction.
Smith KW; White CM
J Clin Pharmacol; 2022 Sep; 62(9):1079-1085. PubMed ID: 35279835
[TBL] [Abstract][Full Text] [Related]
25. A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients.
Dutta S; Shah R; Singhal S; Singh S; Piparva K; Katoch CDS
Expert Opin Drug Saf; 2024 Feb; 23(2):187-198. PubMed ID: 38063346
[TBL] [Abstract][Full Text] [Related]
26. Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease.
Albosta MS; Grant JK; Taub P; Blumenthal RS; Martin SS; Michos ED
Vasc Health Risk Manag; 2023; 19():421-431. PubMed ID: 37434791
[TBL] [Abstract][Full Text] [Related]
27. [Pharmacological and clinical profile of inclisiran sodium, a long-acting LDL cholesterol lowering siRNA, LEQVIO for s.c. injection syringe 300 mg].
Mikami T; Fujiwara Y; Akahori M; Tomimatsu N; Tamaki Y
Nihon Yakurigaku Zasshi; 2024; 159(4):254-263. PubMed ID: 38945909
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Inclisiran in Asian Patients: Results From ORION-18.
Huo Y; Lesogor A; Lee CW; Chiang CE; Mena-Madrazo J; Poh KK; Jeong MH; Maheux P; Zhang M; Wei S; Han Y; Li Y
JACC Asia; 2024 Feb; 4(2):123-134. PubMed ID: 38371290
[TBL] [Abstract][Full Text] [Related]
29. First clinical experiences with inclisiran in a real-world setting.
Mulder JWCM; Galema-Boers AMH; Roeters van Lennep JE
J Clin Lipidol; 2023; 17(6):818-827. PubMed ID: 37775462
[TBL] [Abstract][Full Text] [Related]
30. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial.
Ray KK; Kallend D; Leiter LA; Raal FJ; Koenig W; Jaros MJ; Schwartz GG; Landmesser U; Garcia Conde L; Wright RS;
Eur Heart J; 2022 Dec; 43(48):5047-5057. PubMed ID: 36331315
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials.
Raal F; Abelson M; Blignaut S; Burgess L; Coetzer S; Ebrahim I; Gibbon A; Jansen van Rensburg D; Jaros M; Lombard L; Van Nieuwenhuizen E; Pretorius M; Van Tonder A; Urbach D
S Afr Med J; 2022 May; 112(6):426-432. PubMed ID: 36217872
[TBL] [Abstract][Full Text] [Related]
32. Inclisiran: How Widely and When Should We Use It?
Pirillo A; Catapano AL
Curr Atheroscler Rep; 2022 Oct; 24(10):803-811. PubMed ID: 35877035
[TBL] [Abstract][Full Text] [Related]
33. Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies.
Brandts J; Ray KK
Curr Opin Lipidol; 2020 Aug; 31(4):182-186. PubMed ID: 32487819
[TBL] [Abstract][Full Text] [Related]
34. Inclisiran, the billion-dollar drug, to lower LDL cholesterol - is it worth it?
Doggrell SA
Expert Opin Pharmacother; 2020 Nov; 21(16):1971-1974. PubMed ID: 32749892
[TBL] [Abstract][Full Text] [Related]
35. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment.
Kallend D; Stoekenbroek R; He Y; Smith PF; Wijngaard P
J Clin Lipidol; 2022; 16(2):208-219. PubMed ID: 35168913
[TBL] [Abstract][Full Text] [Related]
37. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial.
Leiter LA; Teoh H; Kallend D; Wright RS; Landmesser U; Wijngaard PLJ; Kastelein JJP; Ray KK
Diabetes Care; 2019 Jan; 42(1):173-176. PubMed ID: 30487231
[TBL] [Abstract][Full Text] [Related]
38. Small interfering ribonucleic acid for cholesterol lowering - Inclisiran: Inclisiran for cholesterol lowering.
Soffer D; Stoekenbroek R; Plakogiannis R
J Clin Lipidol; 2022; 16(5):574-582. PubMed ID: 35909047
[TBL] [Abstract][Full Text] [Related]
39. High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany.
Makhmudova U; Schatz U; Perakakis N; Kassner U; Schumann F; Axthelm C; Stürzebecher P; Sinning DL; Doevelaar A; Rohn B; Westhoff T; Vogt A; Scholl M; Kästner U; Geiling JA; Stach K; Mensch J; Lorenz E; Paitazoglou C; Eitel I; Baessler A; Steinhagen-Thiessen E; Koenig W; Schulze PC; Landmesser U; Laufs U; Weingärtner O;
Clin Res Cardiol; 2023 Nov; 112(11):1639-1649. PubMed ID: 37422840
[TBL] [Abstract][Full Text] [Related]
40. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia.
Khan SA; Naz A; Qamar Masood M; Shah R
Am J Cardiol; 2020 Nov; 134():69-73. PubMed ID: 32892993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
